Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension.

Experimental and clinical cardiology

Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H, Nishiyama A, Takeda N.
PMID: 18650977
Exp Clin Cardiol. 2007;12(1):33-6.

BACKGROUND: Cardiac hypertrophy and failure are major complications of hypertension.OBJECTIVES: The beneficial effect of treatment with antihypertensive drugs on serum levels of brain natriuretic peptide (BNP) was examined in patients with essential hypertension.METHODS: Antihypertensive drugs were administered to 88...

Cite
Shikata C, Sekikawa T, Kimura N, et al. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Exp Clin Cardiol. 2007;12(1):33-6
Shikata, C., Sekikawa, T., Kimura, N., Kojima, A., Seki, S., Oka, H., Nishiyama, A., & Takeda, N. (2007). Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Experimental and clinical cardiology, 12(1), 33-6.
Shikata, Chihiro, et al. "Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension." Experimental and clinical cardiology vol. 12,1 (2007): 33-6.
Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H, Nishiyama A, Takeda N. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Exp Clin Cardiol. 2007;12(1):33-6. PMID: 18650977; PMCID: PMC2359624.
Copy Download .nbib Format: NLM
Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.

Acta Cardiologica Sinica

Yang SC, Tsai WI, Liau CS, Wang TD.
PMID: 27122680
Acta Cardiol Sin. 2013 Jan;29(1):11-8.

BACKGROUND: Given the favorable impact of α1-blockers on lipid and glucose metabolism, this study was designed to compare the efficacy of two extended-release α1-blockers (bunazosin and doxazosin) as an add-on treatment in subjects with stage 1 or 2 essential...

Cite
Yang SC, Tsai WI, Liau CS, et al. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Acta Cardiol Sin. 2013;29(1):11-8
Yang, S. C., Tsai, W. I., Liau, C. S., & Wang, T. D. (2013). Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Acta Cardiologica Sinica, 29(1), 11-8.
Yang, Shao-Chi, et al. "Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension." Acta Cardiologica Sinica vol. 29,1 (2013): 11-8.
Yang SC, Tsai WI, Liau CS, Wang TD. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Acta Cardiol Sin. 2013 Jan;29(1):11-8. PMID: 27122680; PMCID: PMC4804956.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries